Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin vs Empagliflozin on FMD in T2DM
NCT04195243Phase 3Unknown
- Sponsor
- Centro Universitario de Ciencias de la Salud
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin, empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Centro Universitario de Ciencias de la Salud. Status: unknown.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04195243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195243.